Investigation of V520 in a HIV Vaccine Dose Refinement Study

Trial Profile

Investigation of V520 in a HIV Vaccine Dose Refinement Study

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Aug 2015

At a glance

  • Drugs V 520 (Primary)
  • Indications HIV infections
  • Focus Pharmacodynamics
  • Sponsors Merck & Co
  • Most Recent Events

    • 22 Sep 2007 Status changed from recruiting to discontinued.
    • 09 Jan 2007 Status change
    • 27 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top